US Patent

US12005069 — Bortezomib compositions

Formulation · Assigned to Maia Pharmaceuticals Inc · Expires 2042-09-23 · 16y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects ready-to-use liquid aqueous bortezomib compositions and methods for preparing and using them in therapeutic applications.

USPTO Abstract

The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.

Drugs covered by this patent

Patent Metadata

Patent number
US12005069
Jurisdiction
US
Classification
Formulation
Expires
2042-09-23
Drug substance claim
No
Drug product claim
Yes
Assignee
Maia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.